Ionis Pharmaceuticals, Inc. Cost of Revenue
Ionis Pharmaceuticals, Inc. (IONS) reported Cost of Revenue of $2.74 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $2.74M, a 34.02% decline year-over-year.
- Ionis Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $2.98M, a 103.90% increase year-over-year.
- Ionis Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $7.96M, a 107.75% increase year-over-year.
- Ionis Pharmaceuticals, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $2.34M, a 118.30% increase year-over-year.
- Ionis Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2025 was $15.91M, a 41.85% increase from fiscal 2024.
- Ionis Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2024 was $11.21M, a 22.80% increase from fiscal 2023.
- Ionis Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2023 was $9.13M, a 35.30% decline from fiscal 2022.
- Ionis Pharmaceuticals, Inc. cost of goods and services sold for fiscal 2022 was $14.12M, a 30.20% increase from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.74M 10-Q · filed 2026-07-29 | $5.72M 10-Q · filed 2026-07-29 | $13.68M derived: sum of 3 quarters · filed 2026-07-29 | $16.02M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $2.98M 10-Q · filed 2026-04-29 | $10.94M derived: sum of 2 quarters · filed 2026-04-29 | $13.28M derived: sum of 3 quarters · filed 2026-04-29 | $17.43M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $7.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.29M derived: sum of 2 quarters · filed 2026-02-26 | $14.45M derived: sum of 3 quarters · filed 2026-07-29 | $15.91M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.34M 10-Q · filed 2025-10-29 | $6.49M derived: sum of 2 quarters · filed 2026-07-29 | $7.95M 10-Q · filed 2025-10-29 | $11.78M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $4.15M 10-Q · filed 2026-07-29 | $5.61M 10-Q · filed 2026-07-29 | $9.44M derived: sum of 3 quarters · filed 2026-07-29 | $10.52M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $1.46M 10-Q · filed 2026-04-29 | $5.29M derived: sum of 2 quarters · filed 2026-04-29 | $6.36M derived: sum of 3 quarters · filed 2026-04-29 | $10.53M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.90M derived: sum of 2 quarters · filed 2026-02-26 | $9.06M derived: sum of 3 quarters · filed 2026-02-26 | $11.21M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.07M 10-Q · filed 2025-10-29 | $5.24M derived: sum of 2 quarters · filed 2025-10-29 | $7.38M 10-Q · filed 2025-10-29 | $10.45M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $4.16M 10-Q · filed 2025-07-30 | $6.31M 10-Q · filed 2025-07-30 | $9.38M derived: sum of 3 quarters · filed 2026-02-26 | $11.57M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.15M 10-Q · filed 2025-04-30 | $5.21M derived: sum of 2 quarters · filed 2026-02-26 | $7.40M derived: sum of 3 quarters · filed 2026-02-26 | $9.94M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.25M derived: sum of 2 quarters · filed 2026-02-26 | $7.79M derived: sum of 3 quarters · filed 2026-02-26 | $9.13M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.19M 10-Q · filed 2024-11-06 | $4.73M derived: sum of 2 quarters · filed 2024-11-06 | $6.07M 10-Q · filed 2024-11-06 | $9.76M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $2.54M 10-Q · filed 2024-08-01 | $3.88M 10-Q · filed 2024-08-01 | $7.57M derived: sum of 3 quarters · filed 2025-02-19 | $9.08M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | $1.34M 10-Q · filed 2024-05-07 | $5.03M derived: sum of 2 quarters · filed 2025-02-19 | $6.54M derived: sum of 3 quarters · filed 2025-02-19 | $11.29M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $5.20M derived: sum of 2 quarters · filed 2025-02-19 | $9.95M derived: sum of 3 quarters · filed 2025-02-19 | $14.12M 10-K · filed 2025-02-19 |
| 2022-09-30 | $1.51M 10-Q · filed 2023-11-02 | $6.26M derived: sum of 2 quarters · filed 2023-11-02 | $10.43M 10-Q · filed 2023-11-02 | $12.66M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $4.75M 10-Q · filed 2023-08-09 | $8.91M 10-Q · filed 2023-08-09 | $11.14M derived: sum of 3 quarters · filed 2024-02-21 | $14.22M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $4.17M 10-Q · filed 2023-05-03 | $6.40M derived: sum of 2 quarters · filed 2024-02-21 | $9.47M derived: sum of 3 quarters · filed 2024-02-21 | $12.43M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $5.30M derived: sum of 2 quarters · filed 2024-02-21 | $8.26M derived: sum of 3 quarters · filed 2024-02-21 | $10.84M 10-K · filed 2024-02-21 |
| 2021-09-30 | $3.08M 10-Q · filed 2022-11-09 | $6.04M derived: sum of 2 quarters · filed 2022-11-09 | $8.62M 10-Q · filed 2022-11-09 | $11.92M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $2.96M 10-Q · filed 2022-08-09 | $5.54M 10-Q · filed 2022-08-09 | $8.84M derived: sum of 3 quarters · filed 2023-02-22 | $11.92M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $2.58M 10-Q · filed 2022-05-04 | $5.88M derived: sum of 2 quarters · filed 2023-02-22 | $8.96M derived: sum of 3 quarters · filed 2023-02-22 | $11.98M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $6.39M derived: sum of 2 quarters · filed 2023-02-22 | $9.40M derived: sum of 3 quarters · filed 2023-02-22 | $11.95M 10-K · filed 2023-02-22 |
| 2020-09-30 | $3.09M 10-Q · filed 2021-11-03 | $6.10M derived: sum of 2 quarters · filed 2021-11-03 | $8.65M 10-Q · filed 2021-11-03 | $9.66M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $3.01M 10-Q · filed 2021-08-04 | $5.56M 10-Q · filed 2021-08-04 | $6.57M derived: sum of 3 quarters · filed 2022-02-25 | $7.54M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $2.55M 10-Q · filed 2021-05-05 | $3.56M derived: sum of 2 quarters · filed 2022-02-25 | $4.53M derived: sum of 3 quarters · filed 2022-02-25 | $5.89M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $1.98M derived: sum of 2 quarters · filed 2022-02-25 | $3.34M derived: sum of 3 quarters · filed 2022-02-25 | $4.38M 10-K · filed 2022-02-25 |
| 2019-09-30 | $967.00K 10-Q · filed 2020-11-04 | $2.33M derived: sum of 2 quarters · filed 2020-11-04 | $3.37M 10-Q · filed 2020-11-04 | $5.19M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $1.36M 10-Q · filed 2020-08-05 | $2.41M 10-Q · filed 2020-08-05 | $4.22M derived: sum of 3 quarters · filed 2021-02-24 | $4.22M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $1.04M 10-Q · filed 2020-05-06 | $2.86M derived: sum of 2 quarters · filed 2021-02-24 | $2.86M derived: sum of 3 quarters · filed 2021-02-24 | $2.86M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $1.82M derived: sum of 2 quarters · filed 2021-02-24 | $1.82M derived: sum of 3 quarters · filed 2021-02-24 | $1.82M 10-K · filed 2021-02-24 |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $0.00 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |